Case ReportParadoxical topiramate-induced hyperphagia successfully treated with PHENTERMINE (cas 122-09-8) in a woman with migraine
-
Add time:09/24/2019 Source:sciencedirect.com
We report a 49-year-old female migraineur who experienced paradoxical hyperphagia and concurrent intrusive food thoughts leading to rapid weight gain and a substantial increase in waist circumference. A significant reduction in migraine frequency was also observed during topiramate treatment, a widely used migraine prophylactic agent which is generally associated with weight loss. Withdrawal of topiramate saw appetite return to baseline levels, however, migraine frequency was again increased. Topiramate was reinitiated in combination with PHENTERMINE (cas 122-09-8), a drug indicated for weight management, without reoccurrence of adverse effects. Migraine control was maintained and progressive weight loss ensued. Combination treatment with phentermine may be a useful strategy should other patients experience this adverse reaction while gaining therapeutic anti-migraine benefit from topiramate.
We also recommend Trading Suppliers and Manufacturers of PHENTERMINE (cas 122-09-8). Pls Click Website Link as below: cas 122-09-8 suppliers
Prev:Clustering of PHENTERMINE (cas 122-09-8) HCL Drug from Online Patient Medication Reviews
Next:Study protocol and rationale for a randomized double-blinded crossover trial of PHENTERMINE (cas 122-09-8)-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Study protocol and rationale for a randomized double-blinded crossover trial of PHENTERMINE (cas 122-09-8)-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa09/25/2019
- Clustering of PHENTERMINE (cas 122-09-8) HCL Drug from Online Patient Medication Reviews09/10/2019
- Original articleUse of PHENTERMINE (cas 122-09-8)-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more09/09/2019
- Clinical ScienceEffects of liraglutide plus PHENTERMINE (cas 122-09-8) in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial09/08/2019
- PHENTERMINE (cas 122-09-8)☆09/07/2019
- Case reportPHENTERMINE (cas 122-09-8) and Coronary Vasospasm–Induced Myocardial Infarction09/06/2019
- Lorcaserin vs. PHENTERMINE (cas 122-09-8) among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes09/05/2019
- Letter to the EditorPHENTERMINE (cas 122-09-8) associated recurrent intracerebral hemorrhage09/04/2019